ABVC BioPharma, Inc. (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes with institutional and other accredited investors, raising approximately $3.39 million in gross proceeds before placement agent fees and offering expenses. The notes carry an aggregate principal amount of $4,106,060, a 17.5% original issue discount, and mature on June 30, 2027. According to the announcement, the notes become convertible eight months after issuance into common stock at 85% of the average of the three volume-weighted average prices for the three trading days immediately prior to conversion, subject to a floor price and adjustments.
The financing matters because it addresses both immediate liquidity and a specific legacy obligation. ABVC said it expects to use net proceeds for general working capital, funding of its subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a definitive release and settlement agreement. That payment is expected to satisfy specified outstanding payment claims and, according to the company, support its ability to pursue broader financing and business development initiatives. Removing that overhang could give ABVC more flexibility as it seeks capital for its development programs.
The offering also fits ABVC’s stated strategy of advancing its pharmaceutical and medical-device portfolio through strategic licensing, subsidiary development, and independent financing. The company has set up dedicated platforms across its principal development areas: AiBtl BioPharma Inc. for central nervous system drug programs, OncoX BioPharma for oncology, ForSeeCon Eye for ophthalmic medical-device development and commercialization, and BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing services as well as an AI biotechnology innovation platform. Through these arrangements, ABVC aims to advance its programs while creating opportunities for licensing revenues, milestone payments, future royalties, and equity value. The company said it continues to evaluate potential strategic financing and capital-market opportunities for its affiliated businesses.
WallachBeth Capital, Inc. acted as placement agent, Hunter Taubman Fischer & Li LLC acted as legal counsel to the company, and Sichenzia Ross Ference Carmel LLP acted as counsel to the placement agent. The notes and the shares issuable upon conversion have not been registered under the Securities Act of 1933 or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption. Additional details are expected in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.
The transaction’s structure carries potential implications for existing shareholders. Because the notes convert at a discount to recent market prices, conversion could result in dilution, and the floor price and adjustment provisions may affect the effective conversion economics. The eight-month lock before conversion and the maturity date also shape the company’s capital structure through mid-2027. For a clinical-stage biopharmaceutical company developing six new drugs in central nervous system and oncology areas and one ophthalmic medical device, ABV-1701/Vitargus®, access to working capital is critical. The private placement provides near-term funding, but the company’s longer-term prospects depend on clinical progress, licensing arrangements, and its ability to finance subsidiaries without relying solely on the parent company’s balance sheet. The original release is available through NEWMEDIAWIRE.
